GHK-Cu half-life & pharmacokinetics

Reported half-life

Estimated minutes to a few hours in plasma; tripeptide rapidly cleaved by plasma aminopeptidases; tissue retention may exceed plasma half-life

The half-life and pharmacokinetic profile of GHK-Cu reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• topical application
• subcutaneous injection
• intravenous infusion (pre-clinical only)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Copper-chelating tripeptide; tissue-remodelling and antioxidant agent

Mechanism context

Half-life interpretation depends on the underlying mechanism. GHK-Cu acts as follows:

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK), a naturally occurring peptide detectable in human plasma, saliva, and urine. The complex forms via coordination of Cu²⁺ to the imidazole nitrogen of histidine and the N-terminal amine, creating a square-planar or distorted square-planar geometry with a stability constant sufficiently high to enable transdermal copper delivery without generating free radical toxicity from labile copper ions.

See the full GHK-Cu research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.